Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine |
| Group B | ACTIVE_COMPARATOR | Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine |
| Group C | ACTIVE_COMPARATOR | Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine | BIOLOGICAL | Intramuscular, single dose |
| GSK Biologicals' acellular pertussis vaccine | BIOLOGICAL | Intramuscular, single dose |
| Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine | BIOLOGICAL | Intramuscular, single dose |
Inclusion Criteria: * At least 18 years of age at the time of the vaccination * Written informed consent has been obtained Exclusion Criteria: * Evidence of confirmed pertussis disease within the previous 5 years * History of diphtheria or tetanus vaccination within the past 5 years Females must ...
It is a combined vaccine developed by GSK Biologicals, part of GSK plc, that targets three bacterial diseases in a single product: diphtheria, tetanus, and pertussis. It is designed to stimulate immune protection against all three infections at once and has been studied as a booster in healthy adults.
It is used to protect against diphtheria, tetanus, and pertussis, also known as whooping cough. The vaccine combines all three components in one injection. Its Phase 3 trial evaluated it as a booster dose in healthy adults aged 18 years and older, a population that can lose immunity over time.
The vaccine is made by GSK Biologicals, the vaccine business of GSK plc, which trades under the ticker GSK. GSK plc is the developer listed for this combined diphtheria, tetanus, and acellular pertussis vaccine candidate.
It has been studied in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently listed as active. The vaccine is an investigational product in clinical development rather than a newly approved product based on this program record.
The program includes one completed Phase 3 trial, NCT01267058, titled Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults. It enrolled 550 participants aged 18 years and older, used an active-controlled design, and was not double-blind. It studied booster vaccination in healthy adult volunteers.